# Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

> **NCT00527735** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 334 (actual)

## Conditions studied

- Lung Cancer
- Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Placebo
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00527735
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-10
- **Final completion:** 2011-12
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00527735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00527735, "Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00527735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*